- Anixa Biosciences announced the issuance of a **Chinese patent (ZL2020800215666)** by the Chinese National Intellectual Property Administration, covering key aspects of the Company's breast cancer vaccine technology.  **[715446_20251020LA01410:0]** 
- This patent provides intellectual property protection for the breast cancer vaccine in China into the **2040s**.  **[715446_20251020LA01410:0]** 
- A **Phase 1 clinical trial** of Anixa's breast cancer vaccine has been recently completed.  **[715446_20251020LA01410:0]** 
- Full clinical results from the Phase 1 trial are scheduled to be presented on **December 11, 2025**, at the San Antonio Breast Cancer Symposium.  **[715446_20251020LA01410:0]**

Anixa Biosciences Secures Chinese Patent for Breast Cancer Vaccine Technology

- Anixa Biosciences announced the **completion of the final patient visit** in its breast cancer vaccine clinical trial on **October 7, 2025**.  **[715446_20251007LA91771:0]** 
- The Phase 1 trial, funded by the U.S. Department of Defense, included **35 women** across three distinct patient cohorts.  **[715446_20251007LA91771:0]** 
- Preliminary results indicate the vaccine is **well tolerated**, with **over 70% of participants demonstrating protocol-defined immune responses**.  **[715446_20251007LA91771:0]** 
- Full clinical results are scheduled to be presented by Cleveland Clinic at the **San Antonio Breast Cancer Symposium on December 11, 2025**.  **[715446_20251007LA91771:0]**

Anixa Biosciences Completes Final Patient Visit in Breast Cancer Vaccine Clinical Trial

- Anixa Biosciences has **completed dosing of the fourth cohort** in its Phase 1 ovarian cancer CAR-T clinical trial, administering **3x10^6 CAR-positive cells per kilogram** to patients, which is a **30-fold increase** compared to the first cohort.  **[715446_20250916LN75078:1]** 
- The trial continues to demonstrate a **positive safety profile**, with no dose-limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity reported.  **[715446_20250916LN75078:1]** 
- **Multiple treated patients remain alive beyond disease-specific median survival benchmarks**, including one patient from the first cohort who is alive **28 months post-treatment**.  **[715446_20250916LN75078:1]** 
- The company anticipates initiating the **fifth cohort** at approximately **1x10^7 cells/kg** following routine safety verification.  **[715446_20250916LN75078:1]**

Anixa Biosciences (ANIX)